Denali Therapeutics Inc.DNLINASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+13.9%
5Y CAGR+17.3%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+13.9%/yr
vs +29.3%/yr prior
5Y CAGR
+17.3%/yr
Recent deceleration
Acceleration
-15.4pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.2x
Strong expansion
Streak
9 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$133.70M+26.8%
2024$105.44M+2.0%
2023$103.35M+14.2%
2022$90.47M+14.4%
2021$79.06M+31.1%
2020$60.33M+29.8%
2019$46.48M+43.7%
2018$32.35M+106.3%
2017$15.68M+33.7%
2016$11.73M-